Accelerated Approval and Expensive Drugs — A Challenging Combination

Interview with Dr. Walid Gellad on strategies for managing the cost of drugs receiving accelerated FDA approval. (09:56)Download Accelerated FDA approval can mean that private payers choose not to cover a drug because of high cost and lack of evidence of efficacy, thwarting patient access, while major government payers must cover the product, directing substantial tax dollars to unproven drugs.